ARAV Aravive Inc

Price (delayed)

$4.16

Market cap

$86.17M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.69

Enterprise value

$15.93M

Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive is based in Houston, Texas and received a Product Development Award ...

Highlights
The company's revenue has surged by 64% QoQ
ARAV's gross profit has soared by 64% QoQ
The company's equity rose by 8% YoY but it fell by 7% QoQ
The company's quick ratio has shrunk by 51% YoY and by 25% QoQ
The company's net income fell by 13% YoY and by 7% QoQ

Key stats

What are the main financial stats of ARAV
Market
Shares outstanding
20.71M
Market cap
$86.17M
Enterprise value
$15.93M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.32
Price to sales (P/S)
8.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.64
Earnings
Revenue
$9.73M
EBIT
-$29.82M
EBITDA
-$28.65M
Free cash flow
-$17.24M
Per share
EPS
-$1.69
Free cash flow per share
-$0.84
Book value per share
$3.14
Revenue per share
$0.48
TBVPS
$4.17
Balance sheet
Total assets
$85.23M
Total liabilities
$21.17M
Debt
$7.63M
Equity
$64.06M
Working capital
$68.1M
Liquidity
Debt to equity
0.12
Current ratio
6.87
Quick ratio
6.71
Net debt/EBITDA
2.45
Margins
EBITDA margin
-294.4%
Gross margin
100%
Net margin
-306.4%
Operating margin
-310%
Efficiency
Return on assets
-39.6%
Return on equity
-51.8%
Return on invested capital
-581.2%
Return on capital employed
-40.5%
Return on sales
-306.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARAV stock price

How has the Aravive stock price performed over time
Intraday
3.48%
1 week
8.33%
1 month
1.22%
1 year
-16.97%
YTD
-26.24%
QTD
-30.43%

Financial performance

How have Aravive's revenue and profit performed over time
Revenue
$9.73M
Gross profit
$9.73M
Operating income
-$30.17M
Net income
-$29.82M
Gross margin
100%
Net margin
-306.4%
The company's revenue has surged by 64% QoQ
ARAV's gross profit has soared by 64% QoQ
ARAV's operating margin is up by 35% since the previous quarter
The company's net margin rose by 34% QoQ

Growth

What is Aravive's growth rate over time

Valuation

What is Aravive stock price valuation
P/E
N/A
P/B
1.32
P/S
8.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.64
The company's EPS rose by 12% YoY
ARAV's P/B is 42% below its 5-year quarterly average of 2.2 and 29% below its last 4 quarters average of 1.8
The company's equity rose by 8% YoY but it fell by 7% QoQ
The company's revenue has surged by 64% QoQ

Efficiency

How efficient is Aravive business performance
Aravive's return on invested capital has shrunk by 57% QoQ
The company's return on sales rose by 34% QoQ
The ROE has decreased by 16% YoY and by 5% QoQ
Aravive's ROA has decreased by 8% YoY and by 2.6% from the previous quarter

Dividends

What is ARAV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARAV.

Financial health

How did Aravive financials performed over time
ARAV's total liabilities has surged by 83% year-on-year and by 14% since the previous quarter
The company's quick ratio has shrunk by 51% YoY and by 25% QoQ
The company's debt is 88% lower than its equity
Aravive's debt to equity has decreased by 20% YoY
The company's debt fell by 15% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.